Russell Investments Group Ltd. Buys 2,443 Shares of Lantheus Holdings, Inc. (NASDAQ:LNTH)

Russell Investments Group Ltd. increased its stake in Lantheus Holdings, Inc. (NASDAQ:LNTH) by 16.8% in the fourth quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The firm owned 16,955 shares of the medical equipment provider’s stock after purchasing an additional 2,443 shares during the period. Russell Investments Group Ltd.’s holdings in Lantheus were worth $1,517,000 as of its most recent filing with the Securities and Exchange Commission.

A number of other large investors have also recently added to or reduced their stakes in LNTH. MML Investors Services LLC boosted its position in shares of Lantheus by 24.6% during the third quarter. MML Investors Services LLC now owns 4,338 shares of the medical equipment provider’s stock worth $476,000 after buying an additional 857 shares during the period. World Investment Advisors LLC acquired a new position in Lantheus during the 3rd quarter worth approximately $60,000. Wilmington Savings Fund Society FSB acquired a new position in Lantheus during the 3rd quarter worth approximately $25,000. Tidal Investments LLC grew its stake in shares of Lantheus by 25.2% during the 3rd quarter. Tidal Investments LLC now owns 17,621 shares of the medical equipment provider’s stock worth $1,934,000 after acquiring an additional 3,547 shares in the last quarter. Finally, GAMMA Investing LLC raised its holdings in shares of Lantheus by 118.0% in the fourth quarter. GAMMA Investing LLC now owns 1,018 shares of the medical equipment provider’s stock valued at $91,000 after purchasing an additional 551 shares during the last quarter. Institutional investors own 99.06% of the company’s stock.

Lantheus Price Performance

Lantheus stock opened at $101.32 on Friday. The company’s 50-day moving average is $95.39 and its 200-day moving average is $95.45. The firm has a market capitalization of $6.94 billion, a PE ratio of 16.86 and a beta of 0.20. Lantheus Holdings, Inc. has a fifty-two week low of $62.59 and a fifty-two week high of $126.89.

Lantheus (NASDAQ:LNTH) last announced its quarterly earnings results on Thursday, February 27th. The medical equipment provider reported $1.34 earnings per share for the quarter, missing analysts’ consensus estimates of $1.57 by ($0.23). Lantheus had a return on equity of 44.29% and a net margin of 28.57%. The business had revenue of $391.11 million for the quarter, compared to analyst estimates of $376.61 million. As a group, analysts expect that Lantheus Holdings, Inc. will post 6.01 EPS for the current year.

Analyst Upgrades and Downgrades

LNTH has been the subject of a number of analyst reports. B. Riley decreased their target price on shares of Lantheus from $127.00 to $122.00 and set a “buy” rating for the company in a research report on Friday, March 21st. Truist Financial increased their price objective on shares of Lantheus from $120.00 to $127.00 and gave the stock a “buy” rating in a research note on Thursday, February 27th. Finally, JMP Securities reaffirmed a “market outperform” rating and issued a $112.00 target price on shares of Lantheus in a research report on Tuesday, January 14th. One investment analyst has rated the stock with a hold rating and seven have given a buy rating to the company. Based on data from MarketBeat.com, the stock has a consensus rating of “Moderate Buy” and an average target price of $129.43.

Insider Activity at Lantheus

In other news, Director Mary Anne Heino sold 53,107 shares of the company’s stock in a transaction that occurred on Monday, March 3rd. The stock was sold at an average price of $94.35, for a total value of $5,010,645.45. Following the transaction, the director now owns 440,399 shares of the company’s stock, valued at approximately $41,551,645.65. This represents a 10.76 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. Also, CFO Robert J. Jr. Marshall sold 10,000 shares of Lantheus stock in a transaction that occurred on Monday, March 17th. The stock was sold at an average price of $100.52, for a total value of $1,005,200.00. Following the sale, the chief financial officer now directly owns 113,860 shares of the company’s stock, valued at approximately $11,445,207.20. The trade was a 8.07 % decrease in their ownership of the stock. The disclosure for this sale can be found here. In the last quarter, insiders have sold 63,109 shares of company stock worth $6,016,046. Company insiders own 1.50% of the company’s stock.

About Lantheus

Lantheus Holdings, Inc develops, manufactures, and commercializes diagnostic and therapeutic products that assist clinicians in the diagnosis and treatment of heart, cancer, and other diseases worldwide. It provides DEFINITY, an injectable ultrasound enhancing agent used in echocardiography exams; TechneLite, a technetium generator for nuclear medicine procedures; Xenon-133, a radiopharmaceutical gas to assess pulmonary function; Neurolite, an injectable imaging agent to identify the area within the brain where blood flow has been blocked or reduced due to stroke; Cardiolite, an injectable Tc-99m-labeled imaging agent to assess blood flow to the muscle of the heart; and PYLARIFY, an F 18-labelled PSMA-targeted PET imaging agent used for imaging of PSMA positive-lesions in men with prostate cancer.